Mandeep Takhar
Overview
Explore the profile of Mandeep Takhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1169
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salami S, Kaplan J, Nallandhighal S, Takhar M, Tosoian J, Lee M, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914029
Purpose: Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the...
2.
Labbe D, Zadra G, Yang M, Reyes J, Lin C, Cacciatore S, et al.
Nat Commun
. 2019 Sep;
10(1):4358.
PMID: 31554818
Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association...
3.
Lee E, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, et al.
Nat Commun
. 2019 Sep;
10(1):4148.
PMID: 31515477
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in either PKD1 or PKD2 genes, is one of the most common human monogenetic disorders and the leading genetic cause of...
4.
Boufaied N, Takhar M, Nash C, Erho N, Bismar T, Davicioni E, et al.
J Pathol
. 2019 Jun;
249(4):411-424.
PMID: 31206668
Prostate cancer is heterogeneous in both cellular composition and patient outcome, and development of biomarker signatures to distinguish indolent from aggressive tumours is a high priority. Stroma plays an important...
5.
Alshalalfa M, Liu Y, Wyatt A, Gibb E, Tsai H, Erho N, et al.
Int J Cancer
. 2019 May;
145(12):3453-3461.
PMID: 31125117
Prostatic small cell neuroendocrine carcinoma (SC/NE) is well studied in metastatic castration-resistant prostate cancer; however, it is not well characterized in the primary setting. Herein, we used gene expression profiling...
6.
Echevarria M, Awasthi S, Cheng C, Berglund A, Rounbehler R, Gerke T, et al.
J Urol
. 2019 May;
202(2):247-255.
PMID: 31107158
Purpose: Most prostate cancer in African American men lacks the ETS (E26 transforming specific) family fusion event (ETS-). We aimed to establish clinically relevant biomarkers in African American men by...
7.
Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins R, et al.
JCO Precis Oncol
. 2019 Feb;
2018.
PMID: 30761387
Purpose: Molecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations. One of these core subtypes, (speckle-type POZ protein) mutant prostate cancer,...
8.
Beksac A, Cumarasamy S, Falagario U, Xu P, Takhar M, Alshalalfa M, et al.
J Urol
. 2018 Dec;
200(6):1241-1249.
PMID: 30563651
Purpose: Multiparametric magnetic resonance imaging is a diagnostic tool for prostate cancer with limited data on prognostic use. We sought to determine whether multiparametric magnetic resonance could predict aggressive prostate...
9.
Berglund A, Rounbehler R, Gerke T, Awasthi S, Cheng C, Takhar M, et al.
Prostate Cancer Prostatic Dis
. 2018 Oct;
22(2):292-302.
PMID: 30367117
Background: Prostate cancer (PCa) tumors harboring translocations of ETS family genes with the androgen responsive TMPRSS2 gene (ETS+ tumors) provide a robust biomarker for detecting PCa in approximately 70% of...
10.
Karnes R, Sharma V, Choeurng V, Ashab H, Erho N, Alshalalfa M, et al.
Clin Cancer Res
. 2018 May;
24(16):3908-3916.
PMID: 29760221
Currently, no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy for high-risk prostate cancer. Here we develop and validate...